Grifols, S.A. (GRFS): Price and Financial Metrics


Grifols, S.A. (GRFS): $12.49

0.61 (+5.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GRFS POWR Grades


  • Growth is the dimension where GRFS ranks best; there it ranks ahead of 97.3% of US stocks.
  • GRFS's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • GRFS's current lowest rank is in the Quality metric (where it is better than 6.35% of US stocks).

GRFS Stock Summary

  • For GRFS, its debt to operating expenses ratio is greater than that reported by 83.16% of US equities we're observing.
  • With a year-over-year growth in debt of 55.66%, Grifols SA's debt growth rate surpasses 84.72% of about US stocks.
  • As for revenue growth, note that GRFS's revenue has grown 44.21% over the past 12 months; that beats the revenue growth of 79.05% of US companies in our set.
  • Stocks that are quantitatively similar to GRFS, based on their financial statements, market capitalization, and price volatility, are HUDI, MFGP, NTCO, MOG.A, and ITRN.
  • Visit GRFS's SEC page to see the company's official filings. To visit the company's web site, go to www.grifols.com.

GRFS Stock Price Chart Interactive Chart >

Price chart for GRFS

GRFS Price/Volume Stats

Current price $12.49 52-week high $17.45
Prev. close $11.88 52-week low $10.10
Day low $11.74 Volume 930,500
Day high $12.50 Avg. volume 918,830
50-day MA $12.12 Dividend yield N/A
200-day MA $12.09 Market Cap 8.47B

Grifols, S.A. (GRFS) Company Bio


Grifols, S.A. develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The company was founded in 1940 and is based in Barcelona, Spain.


GRFS Latest News Stream


Event/Time News Detail
Loading, please wait...

GRFS Latest Social Stream


Loading social stream, please wait...

View Full GRFS Social Stream

Latest GRFS News From Around the Web

Below are the latest news stories about Grifols SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

Grifols, Endpoint Health team up to develop Antithrombin III for Sepsis

Grifols (GIKLY) is collaborating with Endpoint Health to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis.Under the agreement, Grifols will contribute…

Seeking Alpha | February 24, 2022

Endpoint Health Enters into Global Collaboration and Licensing Agreement with Grifols

PALO ALTO, Calif.--(BUSINESS WIRE)--Endpoint Health, Inc., a precision-firstTM therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced that the company has entered into a global collaboration and licensing agreement with Grifols, a leading global producer of plasma-derived medicines, under which Endpoint Health will receive exclusive rights to develop and commercialize Antithrombin III (AT-III) in sepsis. Under the terms of the

Business Wire | February 24, 2022

Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis

BARCELONA, Spain, Feb. 24, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world''s leading producers of plasma-derived medicines, today announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing…

PR Newswire | February 24, 2022

Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis.

Yahoo | February 24, 2022

Grifols S.A. (NASDAQ: GRFS): Aiming For A Higher Share Price

Grifols S.A. (NASDAQ:GRFS) shares, rose in value on Friday, 02/18/22, with the stock price up by 1.36% to the previous days close as strong demand from buyers drove the stock to $11.20. Actively observing the price movement in the last trading, the stock closed the session at $11.05, falling within a range of $11.01 and Grifols S.A. (NASDAQ: GRFS): Aiming For A Higher Share Price Read More »

Stocks Register | February 19, 2022

Read More 'GRFS' Stories Here

GRFS Price Returns

1-mo -0.72%
3-mo 5.40%
6-mo 11.22%
1-year -27.72%
3-year -40.17%
5-year -34.34%
YTD 11.22%
2021 -37.78%
2020 -20.15%
2019 28.71%
2018 -17.77%
2017 44.48%

Continue Researching GRFS

Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:

Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6406 seconds.